Re-evaluation of prophylactic cranial irradiation in limited-stage small cell lung cancer: a propensity score matched analysis

التفاصيل البيبلوغرافية
العنوان: Re-evaluation of prophylactic cranial irradiation in limited-stage small cell lung cancer: a propensity score matched analysis
المؤلفون: Toshinori Soejima, Mitsuru Marudai, Akifumi Kajihara, Kayoko Tsujino, Shuichiro Miyazaki, Nor Shazrina Sulaiman, Yuko Inoue, Shuhei Sekii, Yousuke Ota, Haruka Uezono
المصدر: Journal of Radiation Research
بيانات النشر: Oxford University Press (OUP), 2021.
سنة النشر: 2021
مصطلحات موضوعية: Male, 0301 basic medicine, medicine.medical_specialty, Lung Neoplasms, Health, Toxicology and Mutagenesis, medicine.medical_treatment, Limited stage small cell lung cancer, Kaplan-Meier Estimate, Group A, Gastroenterology, Group B, Oncology/Medicine, 03 medical and health sciences, 0302 clinical medicine, prophylactic cranial irradiation (PCI), Internal medicine, Antineoplastic Combined Chemotherapy Protocols, small cell lung cancer (SCLC), Humans, Medicine, Radiology, Nuclear Medicine and imaging, Propensity Score, Aged, Neoplasm Staging, Chemotherapy, Radiation, Brain Neoplasms, business.industry, Middle Aged, medicine.disease, Combined Modality Therapy, Small Cell Lung Carcinoma, Progression-Free Survival, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Propensity score matching, Conventional PCI, Disease Progression, AcademicSubjects/SCI00960, brain metastasis (BM), Female, AcademicSubjects/MED00870, Cranial Irradiation, limited stage small cell lung cancer (LS-SCLC), Prophylactic cranial irradiation, business, Follow-Up Studies, Brain metastasis
الوصف: We attempted to re-evaluate the efficacy of prophylactic cranial irradiation (PCI) in limited-stage small cell lung cancer (LS-SCLC) with more recent data. A total of 179 patients with LS-SCLC received radical thoracic radiotherapy and chemotherapy at our institution between 1998 and 2018. One hundred twenty-eight patients who achieved complete response (CR), good partial response (PR), and PR without progression for at least for one year after initial therapy were enrolled in this study. These patients were divided into a PCI group (group A, n = 43), and a non-PCI group (group B, n = 85). Survival outcomes were retrospectively evaluated. Because several background factors differed significantly between groups A and B, propensity score (PS) matching was performed as 1:1 match of the two groups. Finally, we analyzed 64 patients (group A/B = 32/32). Median follow-up periods were 53 and 31 months in groups A and B, respectively. There were no significant differences between the groups’ backgrounds. Two-year overall survival (OS) rates were 77% in group A and 62% in group B (p = 0.224). Two-year brain metastasis free survival (BMFS) rates were 85% in group A and 57% in group B (p = 0.008). The number of patients who underwent a brain imaging test for confirmation of no brain metastasis (BM) after radical thoracic radiotherapy and chemotherapy (before PCI) was 84 (group A/B = 32/52). A PS matched analysis for cases of pre-PCI brain imaging group, two-year OS rates for group A/B were 73/59% (p = 0.446). Two-year BMFS rates for group A/B were 91/52% (p = 0.021). Retrospectively, PS matched analysis revealed that adding PCI to LS-SCLC patients who achieved good thoracic control significantly improved BMFS, but OS did not improve.
تدمد: 1349-9157
0449-3060
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8008968151950ffb66dfb74d5636ea24Test
https://doi.org/10.1093/jrr/rrab053Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....8008968151950ffb66dfb74d5636ea24
قاعدة البيانات: OpenAIRE